Search
Troglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Categories: Drugs Used in DiabetesOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent … Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]
Products: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIALPariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801ApprovedPariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.
Synonyms: Recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC)Heterotheca inuloides flower
go.drugbank.com/drugs/DB14331ApprovedHeterotheca inuloides flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Arnica De LA AbuelaRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165mlIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalCOPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than … Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD).
Categories: Drugs for Obstructive Airway DiseasesBordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10788ApprovedInvestigationalBordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, , Suspension for InjectionProducts: PERTAGEN® SUSPENSION FOR INJECTION 0.5 ML/DOSEIsatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalgranted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma. … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.